Literature DB >> 9612109

[Physical therapy of venous diseases].

M Jünger1, A Steins, D Zuder, T Klyscz.   

Abstract

If physical therapy like compression stockings and supervised outpatient vascular exercise programmes are begun early, subjective complaints can be alleviated and ankle flexibility and venous drainage can be improved. Incapacitating congestive diseases such as dermatolipofasciitis and ulcus cruris can be avoided. Once chronic venous congestion has led to joint capsule atrophy, stiffening of the ankle and muscular atrophy in the lower leg, expensive therapeutic measures involving professional physiotherapeutic care become unavoidable. In our own experience physiotherapy is most effective in combination with biomechanical stimulation therapy. Once the patient's equine gait has been eliminated, conventional walking exercise can gradually restore a physiological gait. After successful physiotherapy, an outpatient vascular exercise programme combined with optimized compression therapy contribute decisively to long-term therapeutic success in patients with advanced chronic venous insufficiency. Like coronary sports, vascular exercise programmes are covered by public health insurance. Along with compression therapy, they represent an efficient, cost-effective basic therapy for chronic venous insufficiency.

Entities:  

Mesh:

Year:  1998        PMID: 9612109

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  3 in total

1.  [Therapy of ulcus cruris venosum].

Authors:  S Braun; M Jünger
Journal:  Hautarzt       Date:  2003-11       Impact factor: 0.751

2.  [Conservative treatment of varicose veins].

Authors:  Markus Stücker
Journal:  Hautarzt       Date:  2021-03       Impact factor: 0.751

3.  Chronic venous disorders - common and yet unknown - a study of public awareness and primary symptoms in a selected group of patients.

Authors:  Marcela Nowak; Dorota Mehrholz; Wioletta Barańska-Rybak; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2021-09-17       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.